Abstract
Abstract The recent introduction of olanzapine (Zyprexa) has provided another first-line antipsychotic treatment option in the pharmacologic treatment of psychiatric patients. Unlike clozapine which is restricted to use with refractory schizophrenia, olanzapine is labeled for the management of manifestations of psychotic disorders. This implies a much larger potential treatment population besides schizophrenia, and nurses should consider its use beyond patients with treatment-resistant schizophrenia. Matters of therapeutic dosing, titration, and maintenance dosing are remarkably simple with this compound. With the current availability of olanzapine, nurses will need to be familiar with the issues surrounding conversion from other antipsychotic agents to this new agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Psychiatric Nurses Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
